Monographie - Palonosetron hydrochloride

Posledná aktualizácia :
19/11/2024

Palonosetron hydrochloride

Chemický vzorec

Obchodný názov

Obchodné názvy sú orientačné, a zloženie pomocných látok sa môže líšiť v závislosti od krajiny a výrobcu.

Aloxi	Belgicko, Dánsko, Fínsko, Grécko, Holandsko, Írsko, Island, Japonsko, Kanada, Luxembursko, Maďarsko, Malajzia, Nemecko, Nórsko, Poľsko, Portugalsko, Rakúsko, Rumunsko, Španielsko, Spojené štáty Americké, Švajčiarsko, Švédsko, Taliansko, Turecko, Veľká Británia
Chepatron	India
Cinvex	Turecko
Factoket	Mexiko
Lotisa	Turecko
Onicit	Čile, Ekvádor, Kolumbia, peru, Taliansko
Palohalt	Čile, peru
Paloject	Turecko
Palonosetron	Belgicko, Čile, Ekvádor, Francúzsko, Nemecko, Španielsko, Švajčiarsko, Veľká Británia
Palostar	India
Palzen	India
Vinaltro	Mexiko
Viqet	Mexiko
Vonaxi	Turecko

Odkazy na literatúru : Palonosetron hydrochloride

	Typ	Publikácia
1932	Časopis	Trissel LA, Zhang Y. Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int J Pharm Compound 2004 ; 8,5: 398-403.
1936	Časopis	Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solusions. Ann Pharmacotherapy 2004 ; 38: 1608-1611.
1940	Časopis	Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1950	Časopis	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
1955	Časopis	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
1975	Časopis	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237.
1976	Časopis	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
2009	Časopis	Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2016	Časopis	Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2107	Časopis	Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: 234-236.
2179	Časopis	Trusley C, Ben M, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 1: 82-85.
2196	Časopis	Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2214	Časopis	Ben M, Trusley C,Kupiec T.C, Trissel L.A. Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 6: 520-524.
2227	Časopis	Trusley C, Ben M, Kupiec TC, Trissel LA. Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 2: 156-160.
2228	Časopis	Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173.
2279	Časopis	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2281	Časopis	Ben M, Kupiec T, Trusley C, Trisel LA. Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 5: 460-462.
2286	Časopis	Ben M, Trusley C, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 4: 368-371.
2312	Časopis	Trissel L.A, Trusley C, Kupiec T.C, Ben M. Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. Int J Pharm Compound 2009 ; 13, 1: 78-80.
3459	Časopis	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3928	Časopis	Wu G, Yeung S, Chen F. Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride. Int J Pharm Compound 2017 ; 21, 1: 76-82.
3981	Časopis	He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162?166
4062	Časopis	Wu George, Powers Dan, Yeung S, Chen F, Neelon K. Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection. Int J Pharm Compound 2018 ;22,1:76-85
4310	Časopis	Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

Mentions Légales